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Abstract
Trypanosomatid parasites are the causative agents of many neglected tropical diseases and there is currently considerable
interest in targeting endogenous sterol biosynthesis in these organisms as a route to the development of novel anti-
infective drugs. Here, we report the first x-ray crystallographic structures of the enzyme squalene synthase (SQS) from a
trypanosomatid parasite, Trypanosoma cruzi, the causative agent of Chagas disease. We obtained five structures of T. cruzi
SQS and eight structures of human SQS with four classes of inhibitors: the substrate-analog S-thiolo-farnesyl diphosphate,
the quinuclidines E5700 and ER119884, several lipophilic bisphosphonates, and the thiocyanate WC-9, with the structures of
the two very potent quinuclidines suggesting strategies for selective inhibitor development. We also show that the
lipophilic bisphosphonates have low nM activity against T. cruzi and inhibit endogenous sterol biosynthesis and that E5700
acts synergistically with the azole drug, posaconazole. The determination of the structures of trypanosomatid and human
SQS enzymes with a diverse set of inhibitors active in cells provides insights into SQS inhibition, of interest in the context of
the development of drugs against Chagas disease.
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Introduction
Many millions of individuals are infected with the so-called
‘‘World’s most neglected diseases’’. These include the leishman-
iases, with ,12 million individuals affected [1], and in Latin
America, Chagas disease. The latter affects ,8 million individuals
[2] including ,300,000 in the United States, according to the US
Centers for Disease Control and Prevention [3]). The global
burden of Chagas disease is estimated to be ,$7 billion a year [4].
There are no cures available for the chronic form of the disease
which can involve cardiac myopathy, mega-oesophagus and
mega-colon, although clinical trials with the azole drug posaco-
nazole and a ravuconazole prodrug are in progress [5,6]. Both of
these compounds function by blocking the ergosterol biosynthesis
pathway [7,8] shown in Figure 1A, as described in a recent review
[9].
Ergosterol is an essential membrane sterol in many trypanoso-
matid parasites and plays the same structural role as does
cholesterol in humans. It is synthesized in a lengthy series of
reactions beginning with the condensation of dimethylallyl
diphosphate (DMAPP, Figure 1A) with two molecules of iso-
pentenyl diphosphate (IPP) to form farnesyl diphosphate (FPP) in a
reaction catalyzed by farnesyl diphosphate synthase (FPPS), a
reaction that is inhibited by bisphosphonate drugs [10]. Two FPP
molecules then condense in a ‘‘head-to-head’’ fashion to form
presqualene diphosphate (the ‘‘first-half’’ reaction) which then
undergoes loss of diphosphate, rearrangement, and reduction by
NADPH to form squalene (the ‘‘second-half’’ reaction), Figure 1A
PLOS Pathogens | www.plospathogens.org 1 May 2014 | Volume 10 | Issue 5 | e1004114
[11], both reactions being catalyzed by squalene synthase (SQS).
Squalene is epoxidized (by O2/squalene epoxidase) to form
oxidosqualene, which is then electro-cyclized by oxidosqualene
cyclase (OSC) to form lanosterol. Lanosterol is demethylated by
the 14-a demethylase/P450 system (CYP51), the target of the
azole drugs, and after several more steps, ergosterol, 24-ethyl-
cholesta-5,7,22-trien-3-b-ol, and its 22-dihydro analogs are
produced. Yeasts and fungi also produce ergosterol and the azole
drugs were originally developed as anti-fungals [12] but were later
found to have potent activity against T. cruzi [7,13]. More recently,
SQS inhibitors, quinuclidines (Figure 1B), originally developed as
cholesterol-lowering drug leads [14], have also been found to kill
T. cruzi, in vitro and in vivo [15]. However, more selective SQS
inhibitors are of interest since they would reduce potential side-
effects on steroidogenesis [16]. To begin to contemplate how to
design such selective quinuclidine species, it is desirable to first
learn more about how these compounds inhibit both human and
trypanosomatid SQS, but to date, no such structures have been
reported.
There is also interest in the development of SQS inhibitors with
completely different structures and properties, including com-
pounds that might have multiple sites of action in the ergosterol
biosynthesis pathway (polypharmacology), as well as different
tissue distributions. Other SQS inhibitors that have been
discovered include the thiocyanate WC-9 [17] as well as the
bisphosphonates ibandronate and incadronate. These bisphospho-
nates inhibit both human SQS (HsSQS) and HsFPPS [18–20] and
block cholesterol biosynthesis [19]. Ibandronate is used clinically
to treat osteoporosis and functions by inhibiting FPP biosynthesis
in osteoclasts. Unfortunately, ibandronate binds tightly to human
bone mineral [21] so this so-called nitrogen-containing bisphos-
phonate would not be a good anti-infective lead since it is rapidly
removed from the circulation, but more lipophilic bisphosphonates
[22–24] have poorer bone-binding capacity and have been shown
to kill parasitic protozoa, such as malaria parasites (Plasmodium
spp.), both in vitro and in vivo [23,24]. In malaria parasites, unlike
the situation with T. cruzi, there is no squalene synthase, and cell
growth inhibition by lipophilic bisphosphonates is primarily at the
level of FPPS/GGPPS (geranylgeranyl diphosphate synthase)
inhibition [23].
The structure of human SQS has been reported [25] but gave
little insight into the SQS mechanism of action. More recently, we
reported [26] the structures of a bacterial SQS homolog,
dehydrosqualene synthase (CrtM) from Staphylococcus aureus which
carries out the same first-half reaction as does SQS, formation of
presqualene diphosphate (PSPP, Figure 1A) from FPP. With
CrtM, PSPP then loses diphosphate, and the resulting carbocation
rearranges and loses a proton to form dehydrosqualene, and we
obtained a quinuclidine inhibitor-bound structure, proposed to
mimic one of the carbocation intermediates in catalysis [27]. Based
on these results and those of others [28,29] the SQS mechanism of
action shown in Figure S1 is suggested. There have, however, been
no structures of any trypanosomatid SQS enzyme. Here, we
report the structures of human SQS and T. cruzi SQS bound to a
substrate-like inhibitor (S-thiolo-farnesyldiphosphate, FSPP), as well
as the structures of both enzymes bound to two potent
Author Summary
Chagas disease is caused by the protozoan parasite
Trypanosoma cruzi and affects eight million individuals,
primarily in Latin America. Currently there is no cure for
chronic T. cruzi infections. Unlike humans, this parasite use
a variety of sterols (e.g. ergosterol, 24-ethyl-cholesta-
5,7,22-trien-3 beta ol, and its 22-dihydro analogs), rather
than cholesterol in their cell membranes, so inhibiting
endogenous sterol biosynthesis is an important therapeu-
tic target. Here, we report the first structure of the
parasite’s squalene synthase, which catalyzes the first
committed step in sterol biosynthesis, as well as the
structures of a broad range of squalene synthase inhibitors
active against the clinically relevant intracellular stages,
opening the way to new approaches to treating this
neglected tropical disease.
Figure 1. Biosynthetic pathways and structures of inhibitors. (A) Biosynthesis of ergosterol, cholesterol and staphyloxanthin. (B) Structures of
inhibitors of interest.
doi:10.1371/journal.ppat.1004114.g001
Trypanosoma cruzi Squalene Synthase
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quinuclidine inhibitors (E5700 and ER119884, Figure 1B) which
suggest routes to selective inhibitor development. We also report
six x-ray structures of lipophilic bisphosphonate inhibitors bound
to TcSQS and/or HsSQS, as well as the activity of a series of
lipophilic bisphosphonates against T. cruzi FPPS, TcSQS, and
solanesyl diphosphate synthase (TcSPPS, involved in ubiquinone-9
biosynthesis, Figure 1A), and against T. cruzi amastigotes, plus, we
demonstrate synergistic effects of E5700 and posaconazole against
amastigotes.
Results and Discussion
Structures of T. cruzi and human squalene synthase
bound to FSPP
We expressed, purified and crystallized T. cruzi squalene
synthase and solved its structure using the method of molecular
replacement. TcSQS crystals could only be obtained in the
presence of the substrate-like inhibitor, FSPP. Full experimental
details are given in Materials and Methods. The construct was the
recombinant enzyme described previously [16] in which 24 amino
acids from the membrane-spanning N-terminus and 36 from the
C-terminus were deleted in order to enable high-level production
of active, soluble protein. We also crystallized HsSQS [30] and
solved its structure, again in the presence of FSPP. Full
crystallographic data acquisition and refinement statistics for both
proteins are given in Tables 1 and 2. For the 13 structures
investigated the resolution was in the range 2.06–3.00 A˚ (2.48 A˚,
on average), Tables 1–3.
All TcSQS crystals investigated belong to the space group
P212121 and contain four molecules in the asymmetric unit. The
crystals of HsSQS belong to the space group P21 and contain six
HsSQS molecules in the asymmetric unit. The two enzymes share
44% amino acid identity and have the same fold (Figure 2A, B).
The root-mean-square deviation (RMSD) is 0.87 A˚ for 298
matched Ca atoms within 2 A˚ of each other. A superposition of
the TcSQS and HsSQS structures is shown in Figure 2C. Two
FSPP substrate-analog inhibitor molecules bind to one TcSQS
monomer. One FSPP is located in the allylic diphosphate (prenyl
acceptor) site S1 previously observed in CrtM, Figure 2D, and the
FPP that is expected to bind to this site is involved in the first
diphosphate ionization reaction. Electron densities are in Figure
S2A and (expanded) in Figure S3A. The other is located in the
homo-allylic (prenyl donor) site, S2. The hydrocarbon moiety in
the FSPP in S2 interacts with Ala168, Val171, Gly172, Leu175,
Table 1. Summary of data processing and refinement statistics of TcSQS complex crystals.
Name TcSQS-FSPP TcSQS-E5700 TcSQS-ER119884 TcSQS-BPH1237 TcSQS-BPH1344
PDB code 3WCA 3WCC 3WCE 3WCB 3WCG
Data collection
Resolution (A˚) 25-2.24 (2.32-2.24) 25-2.32 (2.40-2.32) 25-2.75 (2.85-2.75) 25-3.00 (3.11-3.00) 25-2.80 (2.90-2.80)
Space group P212121 P212121 P212121 P212121 P212121
Unit-cell
a/b/c (A˚) 79.13/132.87/141.92 79.07/131.60/143.12 78.81/131.42/142.23 79.40/127.69/142.56 83.09/128.97/144.97
No. of reflections Measured 541693 (53169) 339484 (33701) 184672 (18170) 127795 (11833) 171915 (15479)
Unique 72859 (7185) 65344 (6481) 39259 (3866) 29564 (2752) 39223 (3518)
Completeness (%) 100.0 (100.0) 99.6 (100.0) 100.0 (100.0) 99.1 (94.6) 98.6 (90.1)
Rmerge (%)
a 5.4 (46.2) 6.1 (48.8) 6.8 (47.9) 7.6 (48.9) 5.6 (41.0)
Mean I/s(I) 44.6 (5.4) 34.1 (4.2) 25.4 (4.0) 15.1 (1.6) 23.7 (2.1)
Multiplicity 7.4 (7.5) 5.2 (5.2) 4.7 (4.8) 4.3 (4.1) 4.4 (3.9)
Wilson B 44.4 44.5 55.8 50.0 60.3
Refinement
Rwork (%) 21.5 (26.3) 21.8 (28.0) 22.7 (29.6) 22.7 (34.1) 23.6 (38.9)
Rfree (%) 26.2 (31.1) 25.7 (31.7) 27.6 (34.7) 23.7 (33.3) 26.5 (37.4)
Geometry deviations
Bond lengths (A˚) 0.006 0.006 0.003 0.003 0.004
Bond angles (u) 1.10 1.17 0.89 0.91 0.94
Ramachandran plot (%)
Most favored 95.0 95.0 92.8 94.6 93.5
allowed 4.6 4.3 6.6 4.9 6.1
Disallowed 0.4 0.7 0.6 0.5 0.4
Mean B-values(A˚2)/
No. of atoms
Protein 53.6/11005 52.4/11013 62.6/11001 74.4/11013 78.0/11013
Solvent 54.4/741 52.1/502 49.7/350 51.9/196 55.4/173
Ligand 79.9/123 43.1/128 91.2/120 121.7/64 112.6/120
Values in parentheses are for the highest resolution shell.
aRmerge =ghklgi|Ii(hkl)2,I(hkl).|/ghklgiIi(hkl).
doi:10.1371/journal.ppat.1004114.t001
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Thr176 and Tyr179 from helix aG; Met199, Gly200 and Leu203
from helix aH; Phe282, Ser283 and Pro286 from helix aJ, as well
as Phe45, Tyr64 and Tyr270. The diphosphate group of FSPP in
S2 is located at the N-terminal end of helix aB and interacts with
Ser42, Arg43, Ser44, and Arg68, while the diphosphate group
from the first FSPP (in S1) is adjacent to the DXXED motif in
helix aH. The DXXXD motif is highly conserved in many terpene
synthases and cyclases [31] and is involved in binding to, in
general, 3 Mg2+ that in turn bind to an allylic diphosphate, the
Mg2+ facilitating carbocation formation due to diphosphate loss
[32]. In HsSQS, the hydrocarbon moieties of FSPP bind in a
similar way to the S1 and S2 sites, Figure 2E, but the orientations
of the diphosphate head groups are somewhat different to those
found with TcSQS, as can be seen in the ligand superpositions
shown in Figure 2E, although the IC50 values for SQS inhibition
are quite similar: 31 nM (TcSQS) and 64 nM (HsSQS). Binding
appears to be driven by primarily hydrophobic interactions,
consistent with limited electrostatic interactions with cationic
amino-acid residues and the relatively solvent-accessible positions
of the diphosphate group. Isothermal titration calorimetry results
for the binding of FSPP to TcSQS are shown in Figure S4 and
indicate a Kd of 2.6 mM. All major protein-ligand interactions are
shown in Figure S5A–D.
Structures of SQS with quinuclidine inhibitors
We next obtained the structures of two very potent SQS
inhibitors: the quinuclidines E5700 and ER119884 (Figure 1B)
developed by Eisai Company (Tokyo, Japan) as anti-hypercholes-
terolemia drug leads that also have,1 nM activity against TcSQS
and potent antiproliferative activity against T. cruzi [15,16]. We
solved the structures of the quinuclidines bound to both TcSQS
and HsSQS using the method of molecular replacement. Full data
acquisition and structure refinement details are in Tables 1 and 2
and electron densities are in Figures S2, S6 and S7. In both
proteins the inhibitors span both the S1 and S2 isoprenoid binding
sites, helping explain the very potent enzyme inhibition seen
experimentally. With E5700, the quinuclidine ring occupies the S1
carbocation site (called here S1A) while the opposite end of the
inhibitor is located at the bottom end of the S2 binding site,
Figure 3A. The quinuclidine is expected to bind as a cationic
species (quinuclidine pKa ,10), and likely mimics one of the
carbocations involved in squalene biosynthesis. The phenyl ring in
Table 2. Summary of data processing and refinement statistics of HsSQS complex crystals.
Name HsSQS-FSPP HsSQS-E5700 HsSQS-ER119884 HsSQS-WC-9
PDB code 3WC9 3WCJ 3WCM 3WCD
Data collection
Resolution (A˚) 25-2.82 (2.92-2.82) 25-2.20 (2.28-2.20) 25-2.06 (2.13-2.06) 25-2.75 (2.85-2.75)
Space group P21 P21 P21 P21
Unit-cell
a/b/c (A˚) 85.19/153.33/90.99 85.33/153.63/92.12 85.62/153.45/92.12 85.73/153.74/91.43
b (u) 91.84 90.86 90.86 91.00
No. of reflections Measured 221507 (22296) 387940 (38371) 855441 (84900) 233294 (23130)
Unique 55674 (5574) 120906 (11991) 146577 (14638) 61519 (6087)
Completeness (%) 99.7 (99.4) 99.8 (99.9) 100.0 (100.0) 100.0 (100.0)
Rmerge (%)
a 11.4 (48.3) 8.0 (46.0) 8.2 (49.3) 9.3 (45.8)
Mean I/s(I) 17.9 (4.6) 19.3 (3.1) 27.3 (4.2) 18.5 (3.7)
Multiplicity 4.0 (4.0) 3.2 (3.2) 5.8 (5.7) 3.8 (3.8)
Wilson B 24.2 31.7 26.6 35.7
Refinement
Rwork (%) 18.4 (26.7) 19.8 (28.4) 18.6 (25.1) 19.6 (28.9)
Rfree (%) 24.8 (32.0) 22.5 (30.9) 22.2 (28.0) 24.9 (35.5)
Geometry deviations
Bond lengths (A˚) 0.007 0.007 0.009 0.004
Bond angles (u) 1.20 1.14 1.19 0.90
Ramachandran plot (%)
Most favored 93.6 95.9 96.9 93.2
allowed 5.7 3.6 3.0 6.0
Disallowed 0.7 0.5 0.1 0.8
Mean B-values (A˚2)/No. of atoms
Protein 42.9/16168 43.8/16183 37.5/15965 49.1/16177
Solvent 34.6/833 43.4/825 40.7/1136 44.0/768
Ligand 69.7/168 39.9/192 38.0/180 92.1/76
Values in parentheses are for the highest resolution shell.
aRmerge =ghklgi|Ii(hkl)2,I(hkl).|/ghklgiIi(hkl).
doi:10.1371/journal.ppat.1004114.t002
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the benzyl group occupies the bottom of the S1 binding site (S1B),
as shown in Figure 3A, and the terminal methoxyl group in E5700
(in S2) is closely aligned with the ‘‘tail’’ of the FSPP ligand (in S2).
With the ER119884 inhibitor bound to TcSQS (Figure 3B), the
quinuclidine again binds to S1A and, as with E5700, the benzyl
group occupies S1B, at the terminus of the S1 FPP site. The
methyl terminus of the methoxy-propyl group also again aligns
with the ‘‘tail’’ of the FSPP in S2 (Figure 3B). Detailed protein-
ligand interactions are in Figure S5E–H.
With the HsSQS/quinuclidine structures we were able to obtain
crystals by co-crystallization. However, this was not possible with
TcSQS and it was necessary to soak TcSQS?FSPP crystals with
the quinuclidine inhibitors, raising the possibility that there might
be incomplete FSPP replacement (even in the presence of 10 mM
quinuclidine). We thus show in Figures S3, S5 and S7 expanded
and stereo views of the ligands in the TcSQS structures (FSPP,
E5700 and ER119884) and for comparison, the HsSQS/
quinuclidine densities (Figure S6), all contoured at 3s. As can
be seen in the TcSQS structures (superimposed on the
TcSQS?FSPP structure), the ligand densities are well defined for
all of E5700 (Figure S7A) and for almost all of ER119884
(Figure 3C and S7B).
To begin to see how selective inhibitors might be designed, we
obtained the structures of both E5700 and ER119884 bound to
HsSQS. Data acquisition and structure refinement details are
given in Table 2. We show in Figure 3C a superposition of E5700
bound to TcSQS (cyan) with that of E5700 bound to human SQS
(orange). It is clear that the drug binds to the two enzymes in a
generally similar way, albeit with a slight tilt of the long axis. The
quinuclidinol cage is also rotated by ,70u between the two
structures, changing the OH position by 2.4 A˚ and the cation
center by 1.4 A˚. More intriguing is the observation that at the
bottom of the S2 ligand-binding pocket, TcSQS has Tyr179/
Ser283 while HsSQS has Phe187/Cys289. In the future it may be
possible to design an inhibitor that will not bind to Phe187/
Cys289 in HsSQS, but will H-bond to Tyr179/Ser283 in TcSQS,
since Tyr/Ser are good H-bond acceptors while Cys (and of
course Phe) are not [33,34]. The second quinuclidine, ER119884,
binds in basically the same way as does E5700, with the
quinuclidinol and benzyl groups in S1 while the methoxypropyl
side chain locates to S2, as shown in Figure 3D. And as with the
E5700 structures, the ER119884 structures indicate close prox-
imity to the F/Y and C/S residues that may be targets for more
selective inhibitors.
Table 3. Summary of data processing and refinement statistics of HsSQS complex crystals.
Name HsSQS-BPH1218 HsSQS-BPH1237 HsSQS-BPH1325 HsSQS-BPH1344
PDB code 3WCF 3WCH 3WCI 3WCL
Data collection
Resolution (A˚) 25-2.22 (2.30-2.22) 25-2.50 (2.59-2.50) 25-2.30 (2.38-2.30) 25-2.24 (2.32-2.24)
Space group P21 P21 P21 P21
Unit-cell
a/b/c (A˚) 85.18/153.19/90.11 85.63/153.55/90.40 85.38/153.62/91.16 85.25/153.30/90.93
b (u) 92.37 91.18 90.82 91.48
No. of reflections Measured 679240 (63361) 308267 (30647) 380278 (37204) 671951 (64477)
Unique 111130 (10387) 81157 (8065) 102588 (10055) 110868 (10570)
Completeness (%) 98.3 (92.0) 99.8 (99.1) 99.3 (97.6) 99.2 (94.7)
Rmerge (%)
a 5.8 (27.1) 9.1 (42.7) 7.9 (44.0) 7.4 (32.7)
Mean I/s(I) 30.1 (3.6) 17.0 (4.4) 27.3 (4.7) 28.0 (3.7)
Multiplicity 6.1 (5.2) 3.8 (3.9) 3.7 (3.6) 6.1 (5.2)
Wilson B 37.1 37.6 34.2 34.2
Refinement
Rwork (%) 22.4 (29.9) 19.2 (25.1) 21.7 (28.3) 18.8 (27.9)
Rfree (%) 20.4 (28.0) 25.0 (32.3) 25.3 (33.2) 22.9 (32.4)
Geometry deviations
Bond lengths (A˚) 0.020 0.020 0.006 0.006
Bond angles (u) 1.82 1.86 1.15 1.09
Ramachandran plot (%)
Most favored 96.1 95.4 95.7 95.5
allowed 3.4 3.9 3.9 4.0
Disallowed 0.5 0.7 0.4 0.6
Mean B-values (A˚2)/No. of atoms
Protein 48.8/16177 47.7/16177 43.9/16177 43.4/16177
Solvent 41.0/495 42.1/427 48.8/1370 43.1/1374
Ligand 74.6/150 79.6/217 99.0/186 98.7/30
Values in parentheses are for the highest resolution shell.
aRmerge =ghklgi|Ii(hkl)2,I(hkl).|/ghklgiIi(hkl).
doi:10.1371/journal.ppat.1004114.t003
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Lipophilic bisphosphonates are potent SQS inhibitors
We next sought to find new SQS inhibitors since, although
having extremely potent activity against TcSQS and T. cruzi, the
quinuclidines have not yet provided parasitological cures in vivo,
due most likely to a short mean residence time [15], so new leads
are of interest. In earlier work, Amin et al. [18] reported that
human SQS was inhibited by nitrogen-containing bisphospho-
nate drugs such as ibandronate and incadronate, with low nM Ki
values. Such bisphosphonates are also potent FPPS inhibitors but
are extremely polar (clogP,23) and do not readily enter cells
with Amin et al. reporting only a ,60 mM IC50 in cholesterol
lowering in J774 cells [19]. In addition, as noted previously, such
bisphosphonates bind avidly to bone mineral – a desirable
feature for a bone resorption drug but not, in general, an anti-
infective. The binding of bisphosphonates to bone involves the
interaction of the phosphonate groups, the 1-OH group, as well
as of an unhindered cationic side-chain with the bone surface
[21]. Replacement of the 1-OH group by a 1-H reduces bone
binding, as does introduction of a hydrophobic side-chain which
also greatly increases activity in a variety of cell assays including
cd T cell activation (where FPPS targeting is involved) [35],
tumor cell killing [22] and inhibition of malaria parasite cell
growth [24].
We thus next tested a series of lipophilic bisphosphonates [24],
n-alkyl side-chain analogs of zoledronate (Figure 1B), with or
without 1-OH groups (part of the ‘‘bone-hook’’ that enables
binding to bone mineral) against TcSQS, HsSQS and TcFPPS
(HsFPPS inhibition being reported earlier [24]). We also tested a
subset of these bisphosphonates for their ability to inhibit the
proliferation of the clinically relevant, intracellular, amastigote
form of T. cruzi. Results are shown in Table 4 and Figure 4A. As
can be seen in Figure 4A, we find with SQS inhibition that there is
an increase in potency with increasing chain length up to n = 10–
11, but then potency decreases on further chain elongation, for
both TcSQS and HsSQS. There is no obvious effect of the 1-OH/
1-H group on enzyme inhibition, but for the most active (C11)
species, the HsSQS IC50 values are ,106 higher than with
TcSQS, indicating selectivity for the parasite enzyme. With
TcFPPS, the increase in activity with chain length is less
pronounced (as found also with HsFPPS), and maximum activity
is found with a C6 substituent while the longer chain species are
notably less active, Figure 4B. Activity in T. cruzi cell growth
inhibition increases monotonically with increasing chain length up
to the longest (C15) chain species investigated, Figure 4C, as seen
also with malaria parasite cell growth inhibition [24], an effect that
we attribute [36] in both organisms to the improved logP values
(clogP,3.3–3.8 for the longer chain inhibitors), resulting in
enhanced cell permeability. FPP biosynthesis is not likely to be a
major target with the most effective cell growth inhibitors (the
C10–C15 bisphosphonates) in T. cruzi since they have relatively
weak activity against FPPS and there was no ‘‘rescue’’ afforded by
farnesol, and only a ,20% rescue by geranylgeraniol (at 40 mM)
with BPH-1218, one of the most potent SQS inhibitors. However,
in the presence of BPH-1218 (C10, 4 mM), the content of
exogeneously-acquired cholesterol in T. cruzi epimastigotes
increased from 51% to 71% of total sterols, while that of
Figure 2. Structural comparisons between TcSQS and HsSQS. (A) Overall structure of TcSQS in complex with FSPP. TcSQS and FSPP are shown
in cyan ribbon and purple sticks, respectively. (B) As (A) but for HsSQS in green ribbon (SQS) and yellow sticks (FSPP). (C) Superimposition of TcSQS/
FSPP (cyan/purple) and HsSQS/FSPP (green/yellow) structures. (D) Stereo view of FSPP and TcSQS amino-acid residues. FSPP ligands are in purple
sticks. (E) Superimposition of FSPP ligands in TcSQS (green and yellow) and HsSQS (blue and magenta).
doi:10.1371/journal.ppat.1004114.g002
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endogenous ergosterol and the three major ergosterol related
sterols (24-ethyl-5,7,22-cholestatrien-3b-ol, ergosta-5,7-diene-3b-
ol and 24-ethyl-5,7- cholestadien-3b-ol) decreased from 36% to
15% of total sterols, Figure S8A. The lipophilic bisphosphonates
are thus potent SQS inhibitors that target sterol biosynthesis and
are active in cells. The longer chain compounds are also poorer
inhibitors of TcFPPS (Figure 4B), HsFPPS, a Plasmodium FPPS/
GGPPS [24] as well as HsGGPPS (IC50 = 2 mM for the C12/1-H
species [23], although any ability to inhibit TcFPPS in addition to
TcSQS is of potential interest since this could result in enhanced
efficacy in growth inhibition because FPPS inhibition would yield
less FPP for the SQS-catalyzed reaction. Importantly, the most
potent T. cruzi cell growth inhibitors had low cytotoxicity against
Vero cells, Table 4.
There could of course be other targets for the lipophilic
bisphosphonates, the most likely being solanesyl diphosphate
synthase (SPPS) which produces the C45 diphosphate used in UQ9
(ubiquinone-9) biosynthesis [37]. We tested a subset of inhibitors
against SPPS finding IC50s as low as 60 nM for the C10 species.
However, unlike the situation with SQS, which is involved in
production of the essential ergosterol not produced by humans, it
is possible that SPPS is not an ‘‘essential gene’’ for T. cruzi in
amastigotes, since quinones might be obtained from the host cell.
There is, however, a ,40% decrease in UQ9 biosynthesis with
BPH-1218 in epimastigotes, consistent with multi-site targeting.
We thus believe that reduction in ergosterol (and related
endogenous sterols) is a major contributor to the inhibition of cell
growth. How sterol composition affects cell growth at the
molecular level is not known. However, the azole class [38,39]
of drugs that target ergosterol biosynthesis in fungi have been
shown to lead to progressive alkalinization of yeast vacuoles and a
loss of V-ATPase activity. While not yet examined in trypanoso-
matids, this may also be the ultimate mode of action of this class of
inhibitors, and since the quinuclidines target ergosterol biosynthe-
sis [40], disruption of V-ATPase function, as found with the azoles
in fungi, may also be important.
Figure 3. Crystal structures of E5700 and ER119884 bound to TcSQS and HsSQS. (A) TcSQS/E5700 (PDB ID code 3WCC) superimposed on
TcSQS/FSPP (PDB ID code 3WCA), E5700 in cyan, FSPP in green and yellow. (B) TcSQS/ER119884 (PDB ID code 3WCE) superimposed on TcSQS/FSPP
(PDB code ID 3WCA). ER119884 in blue, FSPP in green and yellow. (C) Superimposed Tc/Hs SQS structures with E5700 (PDB ID codes 3WCC and
3WCJ), showing protein residues of interest. TcSQS in cyan, HsSQS in orange. (D) Superimposed Tc/Hs SQS structures with ER119884 (PDB ID codes
3WCE and 3WCM), showing protein residues of interest. TcSQS in blue, HsSQS in yellow.
doi:10.1371/journal.ppat.1004114.g003
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Structures of lipophilic bisphosphonates bound to SQS
We next investigated the crystallographic structures of four
representative lipophilic bisphosphonates (BPH-1218; BPH-1237;
BPH-1325 and BPH-1344; Figure 1B) bound to TcSQS and/or
HsSQS. These compounds contain C10 or C15 side-chains, with or
without 1-OH groups on the bisphosphonate head-group (BPH-
1218, C10, H; BPH-1237, C10, OH; BPH-1325, C15, OH; BPH-
1344, C15, H). Data acquisition and structure refinement details
are given in Tables 1 (for TcSQS) and 3 (for HsSQS). For TcSQS,
the structure of the shorter-chain (C10) inhibitor (BPH-1237) is
shown, superimposed on FSPP from the TcSQS/FSPP structure,
in Figure 5A, and that of the longer chain (C15) inhibitor (BPH-
1344) is shown superimposed on FSPP in Figure 5B. In both
structures the S2 farnesyl-binding site is occupied by the n-alkyl
side-chains, and the methyl terminus of each inhibitor reaches the
same position, as do the terminal methyl groups in FSPP (as seen
also with the quinuclidine inhibitors). With TcSQS, the electron
density with the shorter chain inhibitor is well defined (Figure S2)
and it is clear that the imidazolium and bisphosphonate groups
occupy S2, Figure 5A. With the longer chain inhibitor (BPH-
1344), the density is broken in several places, but the n-alkyl side
chain spans both S1 and S2 sites, with strong bisphosphonate
fragment density. We attribute this to the presence of multiple
conformations in the middle part of the side chain.
For HsSQS, co-crystallizations with BPH-1218, BPH-1237,
BPH-1325 and BPH-1344 were all successful and strong electron
densities were obtained in all cases (Figure S2). With the shorter
chain inhibitors, there are several ways in which the bisphospho-
Table 4. IC50 values (in mM) for lipophilic bisphosphonates inhibiting T. cruzi and human SQS and FPPS, T. cruzi amastigote cell
growth and Vero (host) cell growtha.
BPH # Structure TcSQS HsSQS TcFPPS HsFPPS T. cruzi amastigotesb,c Vero cellsd
91 C-0,OH .10 .10 0.16 0.10 .10 N.D.
1223 C-1,OH .10 .10 0.22 0.080 .10 N.D.
1335 C-2,OH .10 .10 0.11 0.049 .10 N.D.
1336 C-3,OH .10 .10 0.33 0.034 .10 N.D.
1260 C-4,OH .10 .10 0.37 0.030 .10 N.D.
1324 C-5,OH .10 .10 0.18 0.049 .10 N.D.
1239 C-6,OH 3.1 3.0 0.12 0.044 .10 N.D.
1323 C-7,OH 0.37 0.68 0.09 0.040 .10 N.D.
1222 C-8,OH 0.11 0.27 0.15 0.036 9.361.8 50 61.4
1238 C-9,OH 0.021 0.075 0.22 0.080 7.061.0 190640
1237 C-10,OH 0.018 0.089 0.13 0.23 3.560.3 3806100
1236 C-11,OH 0.030 0.11 0.55 0.21 6.461.1 4606250
1269 C-12,OH 0.046 0.13 0.74 0.49 3.060.02 .125
1322 C-13,OH 0.064 0.18 1.07 4.2 1.260.3 100640
1338 C-14,OH 0.12 0.24 .5 42 1.260.1 51610
1325 C-15,OH 0.10 0.27 .5 60 3.061.0 65618
301 C-0,H .10 .10 0.26 0.14 .10 N.D.
1224 C-1,H .10 .10 0.37 0.19 .10 N.D.
1227 C-2,H .10 .10 0.31 0.08 .10 N.D.
1337 C-3,H .10 .10 0.39 0.066 .10 N.D.
1215 C-4,H .10 .10 0.39 0.079 .10 N.D.
1339 C-5,H .10 .10 0.35 0.11 .10 N.D.
1216 C-6,H 2.0 2.7 0.09 0.058 .10 N.D.
1326 C-7,H 0.21 0.72 0.12 0.044 .10 N.D.
1217 C-8,H 0.06 0.21 0.16 0.040 .10 N.D.
1327 C-9,H 0.016 0.10 0.085 0.043 1062 ,1 mM
1218 C-10,H 0.017 0.053 0.30 0.10 3.160.6 ,1 mM
1328 C-11,H 0.010 0.11 0.39 0.28 4.061.3 ,1 mM
703 C-12,H 0.052 0.14 0.90 0.37 1.160.4 ,1 mM
1329 C-13,H 0.058 0.22 0.91 0.35 1.160.1 ,1 mM
1219 C-14,H 0.12 0.29 .5 3.0 0.860.3 ,1 mM
1344 C-15,H 0.14 0.26 .5 8.3 1.060.1 ,1 mM
aN. D. = not determined.
bResults are means 6 SD from 2 or 3 independent experiments.
cBenznidazole IC50 = 1.960.9 mM.
dBenznidazole IC50,1 mM.
doi:10.1371/journal.ppat.1004114.t004
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nate head-groups bind (Figure 5C, E). With the des-hydroxy
species BPH-1218, the inhibitor binds to the S2 site in a similar
way to that observed in the TcSQS/BPH-1237 complex, with the
polar head-group interacting with Arg52, Ser53, Ser51, Tyr73,
Asn215 and Arg218. With the 1-OH bearing BPH-1237, the side-
chain binds to the S2 site, but the head-group binds to the S1 site
where it interacts with Arg77, Asp80 and Asp84 of the first
DXXED motif. The imidazolium group of this S1-head/S2-tail
BPH-1237 molecule thus occupies the same cationic binding site
as seen with the quinuclidines. In the case of the two longer chain
(C15) species bound to HsSQS (Figure 5D, F), the last 8 carbons in
both chains locate to the S2 site, but the chain then bends and
occupies the S1 site, basically in the ‘‘bend’’ region seen in CrtM/
PSPP structures [27]. Then, the bisphosphonate polar head-group
returns to the S2 region. This arrangement of the long alkyl chain
presumably minimizes repulsive interactions with the protein since
the binding energies are less than those with the C10 bisphospho-
nates, though as noted above, their improved hydrophobicity
results in better cell growth inhibition. Detailed protein-ligand
interactions for all 6 bisphosphonate structures are shown in
Figure S5I–N.
Structure prediction algorithms such as Phyre 2 [41] predict
that both T. brucei SQS as well as Leishmania amazonensis SQS
(LmSQS) will have similar structures to T. cruzi SQS, making it
likely that the new inhibitors described here will inhibit these
enzymes as well. Moreover, in T. brucei, SQS has been validated as
a drug target by use of RNA interference [42]. It has also been
reported that LmSQS is potently inhibited by several quinucli-
dines including ER119884 and E5700, in the nanomolar/sub-
nanomolar range, and these compounds are active against the
parasites [43]. The selectivity of these drugs was demonstrated
with the JC-1 mitochondrial fluorescent label and by trypan blue
exclusion tests with macrophages, which showed that the IC50s
against the host cells were 4 to 5 orders of magnitude greater that
those against intracellular parasites [15,40,43].
Structure of thiocyanate inhibitor WC-9 bound to human
SQS
In previous work [27] we found that there was close similarity
between the structure of the ligand BPH-652 when bound to CrtM
and HsSQS, in which the ligand binds primarily to S2 – a 2.0 A˚
RMSD for the BPH-652 ligand atoms when using the two aligned
protein structures and only 0.6 A˚ for the two aligned ligands. We
also reported the structure of the thiocyanate inhibitor WC-9
(Figure 1B) bound to CrtM and WC-9 is also known to be an
inhibitor of TcSQS [17]. We were unable to obtain diffraction
quality crystals of WC-9 bound to TcSQS, but we did obtain the
crystal structure of WC-9 bound to HsSQS, as shown in Figure 6A.
Figure 4. Enzyme and cell growth inhibition results. (A) TcSQS and HsSQS inhibition by bisphosphonates as a function of n, the number of
carbons in the n-alkyl group. For n,6, the IC50 values are larger than 10 mM; (B) As (A) but for TcFPPS and HsFPPS. (C) T. cruzi amastigote cell growth
inhibition by bisphosphonates as a function of n. (D) Isobologram showing the synergistic effect of E5700 and posaconazole against T. cruzi
amastigotes after 96 h of treatment. Dashed line corresponds to the predicted positions of the experimental points for additive effects.
doi:10.1371/journal.ppat.1004114.g004
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The ligand again appears to bind to S2 [44], however, when we
compare the CrtM and HsSQS/WC-9 structures, Figure 6B, it is
clear that there is a shift in the position of the S2 site (denoted S2*
in Figure 6B).
Comparisons between squalene and dehydrosqualene
synthase structures
The results described above are also of interest when compared
with earlier results on the bacterial dehydrosqualene synthase
(CrtM, from Staphylococcus aureus) since they highlight two similar
inhibitor structural features. The first observation is that the
quinuclidine ring in E5700 as well as in ER119884 occupies a
similar (S1A) binding site to that seen in the SQS/CrtM
quinuclidine inhibitor BPH-651 (Figure 1B) bound to CrtM
(Figure 7A). This site is also occupied by the adamantane ring in
the CrtM inhibitor [44] SQ-109 (Figures 1B and 7B) and this site
represents a common lipophilic, cationic binding site. The second
observation of interest is that there is a hydrophobic pocket (S1B)
that is occupied by the benzyl group in E5700 bound to SQS, as
well as to the benzyl group in BPH-702 (Figures 1B and 7C) or the
Figure 5. Complex Structures of SQS with lipophilic bisphosphonate inhibitors. (A) TcSQS/BPH-1237; (B) TcSQS/BPH-1344; (C) HsSQS/BPH-
1237; (D) HsSQS/BPH-1344; (E) HsSQS/BPH-1218; (F) HsSQS/BPH-1325. All structures are superimposed on the corresponding FSPP structures (shown
in green and yellow).
doi:10.1371/journal.ppat.1004114.g005
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benzyl group in BPH-652 (Figures 1B and 7D). These observations
suggest that it may be possible to improve the activity of other
inhibitors (such as the bisphosphonates) by incorporating benzyl
groups that can bind to S1B.
Synergy between E5700 and the lanosterol 14a-
demethylase inhibitor posaconazole
The results described above provide information on the
molecular basis for the potency of the aryl-quinuclidines as SQS
inhibitors and potential future strategies for the design of parasite-
specific inhibitors. The potency of these compounds might also be
enhanced by using them in combination with other inhibitors,
acting at different steps in the ergosterol biosynthesis pathway [45].
We tested this idea using a combination of E5700 and posaconazole
(a very potent lanosterol 14a-demethylase (P450) inhibitor in clinical
trials for Chagas disease) on intracellular amastigotes cultured inside
murine peritoneal macrophages using the methodology described
previously to investigate the combined effects of amiodarone and
posaconazole [46]. As can be seen in Figure 4D, we obtain a
concave isobologram with a fractional inhibitory concentration
index (FICI) of 0.36, which indicates synergism since the accepted
value for synergistic effects is FICI,0.5 [47].
In summary, in this work we report the structure of squalene
synthase from Trypanosoma cruzi, a potentially important target for
the development of novel therapeutic agents for the treatment of
Chagas disease. The SQS protein structure had two major
hydrophobic pockets: The S1 allylic binding site in which
FSPP(FPP) binds to a cluster of highly conserved Asp residues
via Mg2+, and a homoallylic S2 binding site to which the second
FPP binds via basic residues interacting with the FSPP’s
diphosphate group. We solved the structures of two potent SQS
inhibitors, the quinuclidines E5700 and ER119884, bound to both
TcSQS as well as HsSQS. The results show that in all four cases,
the more distal parts of the hydrophobic side-chains occupy
primarily the S2-like FPP-binding site, while the benzyl groups
bind to S1B and occupy the same position as the terminal methyl
groups in the S1 FPP. The quinuclidinol groups occupy the S1A
site where cationic species have been found to bind in the bacterial
SQS homolog, CrtM. There were, however, several differences in
inhibitor as well as amino-acid side-chain structures between
TcSQS and HsSQS, opening up the possibility of selective
inhibitor design. We also screened a library of lipophilic
bisphosphonates against TcSQS, HsSQS, TcFPPS and T. cruzi
amastigote cell growth. Most potent inhibition was found against
TcSQS with a C11 side-chain, but the most potent activity in cells
was with a C15 compound, due we propose to its enhanced
hydrophobicity and hence, better cell penetration. There was no
or little rescue from cell growth inhibition by farnesol or
geranylgeraniol, but ergosterol biosynthesis, essential for parasite
survival, was inhibited, consistent with an SQS target. We then
determined the structures of four bisphosphonates bound to
HsSQS and two of these bound to TcSQS. The results showed
that in all cases,8 carbons at the chain terminus bound to S2 and
were closely superposed on the more distal parts of the FSPP
binding sites while the imidazolium rings bound close to the
cationic binding sites identified earlier in CrtM. With the longer
chain compounds, the upper part of the n-alkyl side-chain (close to
the bisphosphonate head group) occupied the S1A pocket that is
occupied by the ‘‘kinked’’ part of the FSPP structure, seen also in
CrtM (+FSPP or PSPP) structures [27]. The polar head-groups
bound primarily to the S2 head-group region. Both the
bisphosphonates as well as the quinuclidine inhibitors thus bind
to both the S1 and S2 substrate-binding sites, providing potent
inhibition, leading to strong antiparasite activity. We also found
strong synergy between the quinuclidine E5700 and and the 14a-
demethylase inhibitor posaconazole, suggesting new therapeutic
possibilities. Overall, the results presented here are of interest in
the context of the future development of squalene synthase
inhibitors as anti-infective drug leads against diseases caused by
trypanosomatid parasites – the neglected tropical diseases.
Materials and Methods
Protein expression and purification
The constructs of TcSQS and HsSQS were obtained as
described previously [16,30]. TcSQS expression was induced with
Figure 6. Structures of WC-9 bound to HsSQS and CrtM. (A) Stereo view of WC-9 bound to HsSQS. The 2Fo - Fc map is contoured at 1s. (B)
Structure of WC-9 bound to CrtM (yellow), overlaid with WC-9/HsSQS structure (blue).
doi:10.1371/journal.ppat.1004114.g006
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0.8 mM isopropyl b-thiogalactopyranoside (IPTG) at 25uC for
18 hours, and HsSQS with 1.0 mM IPTG at 37uC for 6 hours.
Cell pastes were harvested by centrifugation at 4,0006 g for
15 min and resuspended in a lysis buffer containing 25 mM Tris-
HCl, pH 7.5, 20 mM imidazole, and 150 mM NaCl. Cell lysates
were prepared with a French pressure cell press (AIM-AMINCO
Spectronic Instruments), and then centrifuged at 17,0006 g for
30 min to remove cell debris. The cell-free extract was loaded
onto lysis buffer-equilibrated Ni-NTA columns, followed by
washing with 20 mM imidazole-containing buffer. The His-
tagged enzymes were then eluted with an imidazole gradient from
20–250 mM, dialyzed twice against 5 L of 25 mM Tris-HCl,
pH 7.5, and loaded onto a 20 ml DEAE Sepharose Fast Flow
column (GE Healthcare Life Sciences). The buffer and gradient
were 25 mM Tris, pH 7.5, and 0–500 mM NaCl. Purity of the
recombinant proteins (.95%) was checked by SDS-PAGE
analysis.
Inhibition of SQS, FPPS and SPPS activity
Initial SQS enzyme inhibition assays were carried out, in
duplicate, in 96-well plates, with a total of 200 mL of reaction
mixture in each well. Reactions were monitored by using a
continuous spectrophotometric assay for phosphate releasing
enzymes [26]. Reaction buffer contained 50 mM Tris-HCl,
1 mM MgCl2, 450 mM FPP, pH 7.4. The compounds investigated
were pre-incubated with 2 mg of SQS for 30 min at 20uC. The
IC50 values were obtained by fitting the inhibition data to a
normal dose–response curve, using GraphPad PRISM, version
4.0, software for Windows (GraphPad Software Inc., San Diego,
CA, www.graphpad.com). We then verified the results by using a
radioactivity assay using 3H-labelled FPP as substrate. The
reaction mixture (50 mL) had 2.5 nM T. cruzi or H. sapiens SQS,
0.5 mM [1-3H]-FPP, and 250 mM NADPH, in a detergent-
containing buffer (50 mM HEPES-KOH, pH 7.5, 100 mM NaCl,
4 mM MgCl2, 0.5% Tween 80, 2 mM CHAPS, and 4 mM DTT).
Figure 7. Comparisons between TcSQS/E5700 and CrtM/inhibitor structures. The CrtM inhibitors are: (A) BPH-651 (PDB ID code 3ACW). (B)
SQ-109 (PDB ID code 4EA2). (C) BPH-702 (PDB ID code 3ACY). (D) BPH-652 (PDB ID code 2ZCQ).
doi:10.1371/journal.ppat.1004114.g007
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The enzymes were incubated with inhibitor for 10 minutes before
addition of the substrates. The reaction was allowed to continue at
37uC for 15 minutes and then terminated with 50 mL of 0.1 M
NaOH/methanol. The product was extracted with 500 mL of
hexanes and 300 mL of the organic layer was measured by
scintillation counting.
For FPPS inhibition we used the methods described previously
[22]. The condensation of geranyl diphosphate (100 mM) and
isopentenyl diphosphate (100 mM) was monitored at room
temperature by using a continuous spectrophotometric assay for
phosphate releasing enzymes [48]. The reaction buffer contained
50 mM Tris-HCl, pH 7.4, 1 mM MgCl2, and 0.01% Triton
X100. The compounds investigated were pre-incubated with
enzyme for 30 min at room temperature. The IC50 values were
obtained from fitting dose-response curve using Prism 4.0
(GraphPad Software, Inc., La Jolla, CA, www.graphpad.com).
The activity of T. cruzi SPPS was determined by a radiometric
assay [37]. Briefly, 100 mL of assay buffer (100 mM Tris–HCl
buffer, pH 7.4, 1 mM MgCl2, 1% (v/v) Triton X-100, 7.07 mM
[4-14C]-IPP (10 mCi/mmol)), and 50 mM GGPP was pre-warmed
to 37uC. The assay was initiated by the addition of 10–20 ng of
recombinant protein. The assay was allowed to proceed for
30 min at 37uC and was quenched by chilling quickly in an ice
bath. The reaction products were extracted with 1 mL of 1-
butanol saturated with water. The organic layer was washed with
water saturated with NaCl, and transferred to a scintillation vial
with 4 mL of Ecolume scintillation solution for counting. One unit
of enzyme activity was defined as the activity required to
incorporate 1 nmol of [4-14C]-IPP into [4-14C]-FPP in 1 min.
T. cruzi cell growth inhibition
Gamma-irradiated (2,000 Rads) Vero cells (3.46104 cells/well)
were seeded in 96 well plates (black, clear bottom plates from
Greiner Bio-One) in 100 mL RPMI media (Sigma) with 10% FBS.
Plates were incubated overnight at 35uC and 7% CO2. After
overnight incubation, Vero cells were challenged with 3.46105
trypomastigotes/well (CL strain overexpressing a tdTomato red
fluorescent protein) in 50 mL volume and incubated for 5 h at
35uC and 7% CO2. After infection, cells were washed once with
Hanks solution (150 mL/well) to eliminate any extracellular
parasites, and compounds were added in serial dilutions in RPMI
media in 150 mL volumes. Each dilution was tested in quadrupli-
cate. Each plate also contained controls with host cells and no
parasites (for a background check), and controls with parasites and
no drugs (positive control). Drugs were tested at 5 different
concentrations (highest 25 mM). For each set of experiments,
benznidazole was used as a positive control. After drug addition,
plates were incubated at 35uC and 7% CO2. At day 3 post-
infection, plates were assayed for fluorescence and IC50 values
were determined by non-linear regression analysis using Sigma-
Plot.
Sterol biosynthesis inhibition
T. cruzi epimastigotes were grown for 72 hours at 28uC in liver
infusion tryptose medium [49] supplemented with 10% heat
inactivated fetal bovine serum in the absence or presence of 2 mM
BPH-1218. Cells from cultures (96 h incubation) were washed
with Buffer A with glucose (116 mM NaCl, 5.4 mM KCl, 0.8 mM
MgSO4, 5.5 mM D-glucose, and 50 mM HEPES at pH 7.0) then
pelleted and chloroform/methanol (2:1 v/v) added (,30 mL of
solvent per gram of wet cells) followed by vigorous stirring and
overnight incubation at 4uC. The extract was then filtered using
Whatman #2 paper to eliminate insoluble material, and the
filtrate (a single phase) dried under nitrogen. The extract was then
re-extracted using chloroform/methanol 9/1 v/v, dried under
nitrogen, dissolved in 1 mL of pure chloroform and re-dried under
nitrogen gas. The extracted lipids were saponified with 5 mL of
ethanolic-potassium hydroxide (5 g KOH, 7 mL water, 14 mL
ethanol) for 1 hour at 80uC. After cooling, 2.5 mL of water and
1.5 mL hexane were added and the phases allowed to separate.
The aqueous phase was then re-extracted twice with hexane. The
hexane extracts were dried under nitrogen, dissolved in chloro-
form and converted to the trimethylsilyl derivatives by using bis-
trimethylsilyl amide. Both standards and samples (1 mL) were
injected in split mode (10:1) on a GC/MS system, which consisted
of an Agilent 6890 gas chromatograph, an Agilent 5973 mass
selective detector and an HP 7683B (Agilent Inc, Palo Alto, CA,
USA) auto-sampler. Samples were analyzed on a 30 m DB5
column with 0.32 mm I.D. and 0.25 mm film thickness (Agilent
Inc, Palo Alto, CA, USA) with an injection port temperature of
300uC, the interface was set to 300uC, the ion source adjusted to
230uC, MS Quadrupole 150uC. The helium carrier gas was set at
a constant flow rate of 2.7 mL min21. The temperature program
was: 2 min at 250uC, followed by an oven temperature increase of
25uC min21 to 320uC, for 10 min. The mass spectrometer was
operated in positive electron impact mode (EI) at a 69.9 eV
ionization energy in the m/z 50–800 scan range. The spectra of all
chromatogram peaks were evaluated by using the HP Chemsta-
tion (Agilent, Palo Alto, CA, USA) program. Identifications and
quantifications were performed using mass spectra obtained from
authentic standards and with NIST08 and W8N08 libraries (John
Wiley & Sons, Inc., USA).
Quinone extraction and analysis
For ubiquinone extraction, epimastigotes (1 g wet weight) were
washed twice with buffer A with glucose (116 mM NaCl, 5.4 mM
KCl, 0.8 mM MgSO4, 5.5 mM D-glucose, and 50 mM HEPES at
pH 7.0). To break the cells, the pellets were frozen in a dry ice-
100% ethanol bath (for 7 min) and thawed at 37uC (for 3 min) for
a total of 5 times. One volume of water and three volumes of 1-
propanol were added to the pellet. The samples were vortexed for
30 sec at room temperature and allowed to stand for one minute.
Two volumes of n-hexane were added, the mixture vortexed for
30 sec at room temperature, then centrifuged at 12,0006 g for
5 min. The upper phase, containing ubiquinone, was collected
into a glass tube, and dried under nitrogen gas, then analyzed
using LC-MS.
LC/MS was performed using an Agilent LC/MSD Trap XCT
Plus system (Agilent Technologies, Santa Clara, CA) with an 1100
series HPLC system including a degasser, an auto-sampler, a
binary pump, and a multiple-wavelength detector. The LC
separation used a Phenomenex Gemini 3u C18 110A column
(2 mm6100 mm) (Torrence, CA) with mobile phase A (0.1%
formic acid in water) and mobile phase B (0.1% formic acid in
acetonitrile). The flow-rate was 0.25 mL/min. The linear gradient
was as follows: 0–1 min, 100% A; 7–50 min, 0% A; 51–56 min,
100% A. The auto-sampler was set at 5uC and the injection
volume was 15 mL. UV signals were recorded at 275 nm. Positive
ion mass spectrometry used atmospheric pressure chemical
ionization (APCI). The capillary voltage was 4000 V and the
nebulizer pressure and drying gas flow were 60 psi, 7 L/min,
respectively. Temperatures for drying gas and APCI Vap were
350uC and 400uC, respectively.
Isothermal titration calorimetry (ITC)
ITC experiments were carried out basically as described
previously for ligands binding to FPPS [50]. The thermodynamic
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parameters were: DG =232.1 kJ?mol21, DH=210.4 kJ?mol21,
DS= 74.3 J?mol21?K21, and n = 1.86.
Cell growth inhibition by E5700+ posaconazole
The method used to determine possible synergism between the
quinuclidine E5700 and the azole posaconazole followed that
described by Veiga-Santos et al [46].
Measuring Vero cell proliferation using alamarBlueTM
Vero cells (1.76104 cells/well) were seeded in 96 well plates
(black, clear bottom from Greiner Bio-One Cat#655090) in
100 mL RPMI media (Sigma Cat# R-4130) with 10% FBS. Plates
were tested as described by Recher et al [51].
Protein crystallization, data collection and structure
determination
Initial crystallization screening was performed using Hampton
Research Crystal Screens (Laguna Niguel, CA, USA) with the
hanging-drop vapor-diffusion method at room temperature. In
general, 2 mL TcSQS protein solution (8 mg/mL TcSQS enzyme,
25 mM Tris-HCl, pH 7.5, 2.5 mM FSPP) was mixed with 2 mL of
reservoir solution. Single crystals were obtained in 0.1 M Tris,
pH 8.5, 21% PEG 3350. The crystals were mounted in a cryo-
loop and flash-frozen in liquid nitrogen with 0.15 M Tris, pH 8.5,
25% PEG3350 and 8% glycerol as a cryo-protectant. For HsSQS,
2 mL protein solution (5 mg/mL HsSQS enzyme, 25 mM Tris-
HCl, pH 7.5) was mixed with 2 mL of reservoir solution. Single
crystals were obtained in 0.2 M sodium citrate, pH 8.2, 28% PEG
3350. Prior to data collection at 100 K, the crystals were mounted
in a cryo-loop and flash-frozen in liquid nitrogen with 0.3 M
sodium citrate, pH 8.2, 30% PEG3350 and 2% glycerol as a cryo-
protectant.
Crystals of TcSQS could only be obtained in the presence of
FSPP, and direct co-crystallization of TcSQS with ER119884 and
E5700 was not successful. Instead, we soaked the crystals of the
TcSQS-FSPP complex with cryo-protectant solution containing
10 mM ER119884 or E5700 for at least 4 hrs prior to data
acquisition. Crystals of (human) HsSQS in complex with the
inhibitors FSPP, ER119884, E5700, BPH-1218, BPH-1237 and
BPH-1325 were obtained by co-crystallization under similar
conditions (0.2 M sodium citrate, pH 8.2, 24–28% PEG 3350,
5 mM inhibitor concentration).
Diffraction data were collected at beam lines BL13B1 and
BL13C1 of the National Synchrotron Radiation Research Center
(NSRRC, Hsinchu, Taiwan), and processed using the program
HKL2000. Prior to structure refinement, 5% randomly selected
reflections were set aside for calculating Rfree as a monitor of
model quality. The crystal structure of TcSQS was solved by using
the molecular replacement (MR) method using the CNS program
[52]. The previously determined HsSQS structure (PDB code
3VJA) was used as a search model (since it has 44% identity to
TcSQS). The TcSQS crystal belongs to the space group P212121
and contains four protein molecules in an asymmetric unit. The
other TcSQS-drug complex structures were solved by using the
refined TcSQS (but without the bound FSPP) as a starting model.
All crystals of HsSQS belong to the space group P21 and contain
six protein molecules in the asymmetric unit. NCS restraints were
applied at early stages of refinement and released at later stages.
The refinement of every structure started with a temperature
factor (B-factor) of 30, but upon rigid-body refinement an overall B
was calculated for best scaling, which should be close to the
corresponding Wilson B-factor. The individual atomic B-factors
were not restrained by NCS and average B values are shown for
the protein, ligand and solvent atoms in Tables 1–3. The rmsd
between the four monomers of TcSQS ranged from 0.34 to
0.68 A˚ for 341 Ca atoms. The rmsd between six HsSQS
monomers were 0.23–0.80 A˚ for 324–335 Ca atoms. The rmsd
between TcSQS and HsSQS were larger, ranging from 0.82 to
1.28 A˚ for 264–273 Ca atoms.
For all drug molecules, the descriptions of atoms, structures,
chemical bonds and their restraints were compiled into respective
‘‘topology’’ and ‘‘parameter’’ files by using the PRODRG server
[53] for structural refinement by using CNS. Manual adjustments
of the models and addition of water molecules used the program
COOT [54].
Accession numbers
The atomic coordinates and structure factors have been
deposited in the RCSB Protein Data Bank, www.pdb.org for T.
cruzi SQS complexes with FSPP (3WCA), E5700 (3WCC),
ER119884 (3WCE), BPH-1237 (3WCB) and BPH-1344
(3WCG), and human SQS complexes with FSPP (3WC9),
E5700 (3WCJ), ER119884 (3WCM), BPH-1218 (3WCF), BPH-
1237 (3WCH), BPH-1325 (3WCI), BPH-1344 (3WCL) and WC-
9(3WCD).
Supporting Information
Figure S1 Schematic illustration of FPP-to-squalene
reaction catalyzed by SQS. The mechanism is based on the
CrtM crystallographic results by Lin et al. [27]. (A) Bound FPP in
S1 ionizes. (B) Carbocation reacts with S2 FPP alkene group. (C)
PSPP PPi in S2 moves to S1 site. (D) PSPP PPi ionizes. (E and F)
Carbocation rearranges and is reduced by NADPH to form the
final product, squalene. (G) Alternative view of the reaction
mechanism.
(TIF)
Figure S2 Electron density maps of TcSQS and HsSQS
bound ligands. Electron density maps in red and brown
represent 3s and 1s, respectively. (A) to (E) The Fo-Fc omit
maps of FsPP, E5700, ER119884, BPH-1237 and BPH-1344
from TcSQS complex structures and colored in cyan, green,
magenta, blue and yellow, respectively. (F) to (L) The Fo-Fc omit
maps of FsPP, E5700, ER119884, BPH-1344, BPH-1237, BPH-
1325 and BPH-1218 from HsSQS complex structures and
colored in cyan, green, magenta, blue, yellow, gray and purple,
respectively.
(TIF)
Figure S3 Ligand electron densities in TcSQS for FSPP,
E5700 and ER119884. The refined models are superimposed on
Fo-Fc difference Fourier maps calculated by omitting the ligands
in question. Each ligand is shown as a stick model with green
carbon atoms. The ‘‘OMIT’’ maps are all contoured at 3.0 s level
and shown as purple mesh representations. (A) TcSQS/FSPP
(PDB ID code 3WCA); (B) TcSQS/E5700 (PDB ID code 3WCC);
(C) TcSQS/ER119884 (PDB ID code 3WCE).
(TIF)
Figure S4 Isothermal titration calorimetry results for
FSPP binding to TcSQS.
(TIF)
Figure S5 Ligplot representations of local interactions. (A)
TcSQS+FSPP, site 1; (B) TcSQS+FSPP, site 2; (C) HsSQS+
FSPP, site 1; (D) HsSQS+FSPP, site 2; (E) TcSQS+E5700; (F)
TcSQS+ER119884; (G) HsSQS+E5700; (H) HsSQS+ER119884; (I)
TcSQS+BPH-1237; (J) TcSQS+BPH-1344; (K) HsSQS+BPH-1218;
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(L) HsSQS+BPH-1237; (M) HsSQS+BPH-1325; (N) HsSQS+BPH-
1344.
(PDF)
Figure S6 Ligand electron densities in HsSQS for FSPP,
E5700 and ER119884. The Fo-Fc ‘‘OMIT’’ maps are
contoured at the 3.0 s level. (A) HsSQS/FSPP (PDB ID code
3WC9); (B)HsSQS/E5700 (PDB ID code 3WCJ); (C) HsSQS/
ER119884 (PDB ID code 3WCM).
(TIF)
Figure S7 Stereo-view of electron densities of quinucli-
dines bound to TcSQS. (A) E5700 and (B) ER119884. The Fo-
Fc ‘‘OMIT’’ maps are contoured at 3.0 s level. The correspond-
ing models are superimposed and shown as cartoon for the protein
and sticks for the ligand, with the carbon atoms colored in green.
For comparison, the aligned structure of TcSQS/FsPP is also
shown, as cartoon and sticks with cyan carbons.
(TIF)
Figure S8 Effects of BPH-1218 on ergosterol and
ubiquinone biosynthesis in T. cruzi epimastigotes. (A)
GC-MS trace for trimethylsilyated sterols and sterol compositions
(+drug %; 2drug % and +drug/2drug ratios). (B)–(E) LC-MS
and LC-UV results for UQ9 biosynthesis inhibition. (B, C). LC-
MS without (B) or with (C) BPH-1218 in the growth medium. (D,
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